tiprankstipranks
Trending News
More News >
Altimmune Inc (ALT)
NASDAQ:ALT

Altimmune (ALT) AI Stock Analysis

Compare
3,237 Followers

Top Page

AL

Altimmune

(NASDAQ:ALT)

52Neutral
Altimmune's overall score reflects a mix of financial challenges and optimistic future prospects. The strong balance sheet and strategic financial moves provide stability, while upcoming clinical trial results and expansions into new therapeutic areas offer potential growth. However, ongoing profitability and cash flow issues, along with a negative valuation, weigh down the score.
Positive Factors
Clinical Trials
The highly-anticipated Phase 2b trial (IMPACT) readout is a key near-term catalyst for investors.
Financial Position
Altimmune's strong financial position ensures that the IMPACT readout and subsequent FDA interactions are fully funded.
Product Differentiation
Pemvidutide's dual mechanism of action could have beneficial impacts on both weight loss and liver health, which is supported by clinical results.
Negative Factors
Market Competition
Pemvidutide could be the first incretin-based therapy to achieve fibrosis improvement at 24 weeks, setting it apart from both GLP-1 monotherapies and other liver-directed agents.
Valuation
ALT currently seems undervalued trading at a discount to current Phase 3 MASH companies, presenting a significant opportunity to catch up in valuation.

Altimmune (ALT) vs. S&P 500 (SPY)

Altimmune Business Overview & Revenue Model

Company DescriptionAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
How the Company Makes MoneyAltimmune generates revenue primarily through research and development collaborations, government contracts, and grants. The company partners with various organizations to develop and commercialize its product candidates. These partnerships often include milestone payments and royalties based on sales of successfully developed products. Additionally, Altimmune may receive funding from governmental and non-governmental agencies to support its R&D efforts in areas of public health interest.

Altimmune Financial Statement Overview

Summary
Altimmune faces significant challenges in achieving profitability and positive cash flow, as indicated by negative margins and cash flow metrics. However, the company maintains a strong balance sheet with low leverage, providing a cushion for future growth opportunities.
Income Statement
20
Very Negative
Altimmune has shown inconsistent revenue figures over the years, with a significant drop in the most recent period. Gross profit margins have been volatile, and the company has consistently posted negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges in achieving profitability.
Balance Sheet
70
Positive
The company maintains a strong equity position with an equity ratio of 88.65% in the latest period, reflecting a solid balance sheet with minimal debt. The debt-to-equity ratio is favorable, indicating low financial leverage. However, the persistent net income losses have impacted the return on equity, which remains negative.
Cash Flow
30
Negative
Altimmune has experienced negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, reflecting the company's difficulties in translating earnings into cash flow.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
20.00K426.00K-68.00K4.41M8.19M
Gross Profit
20.00K-51.00K-136.00K3.86M-25.32M
EBIT
-103.17M-95.93M-87.74M-96.91M-54.80M
EBITDA
-94.81M-87.94M-84.40M-96.53M-54.15M
Net Income Common Stockholders
-95.06M-88.45M-84.71M-96.17M-49.04M
Balance SheetCash, Cash Equivalents and Short-Term Investments
131.89M197.81M184.88M190.30M215.92M
Total Assets
139.31M210.64M206.93M218.86M245.12M
Total Debt
1.68M671.00K1.12M1.54M1.82M
Net Debt
-35.24M-134.45M-109.97M-188.77M-114.09M
Total Liabilities
15.80M16.54M21.64M19.73M19.24M
Stockholders Equity
123.51M194.10M185.29M199.13M225.88M
Cash FlowFree Cash Flow
-79.85M-75.86M-62.71M-90.55M-34.78M
Operating Cash Flow
-79.85M-75.81M-62.59M-78.24M-34.44M
Investing Cash Flow
-28.39M13.73M-73.40M87.52M-72.09M
Financing Cash Flow
10.04M86.11M56.78M65.10M213.49M

Altimmune Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.58
Price Trends
50DMA
5.19
Positive
100DMA
5.98
Negative
200DMA
6.60
Negative
Market Momentum
MACD
0.19
Negative
RSI
53.84
Neutral
STOCH
62.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Neutral. The current price of 5.58 is above the 20-day moving average (MA) of 5.36, above the 50-day MA of 5.19, and below the 200-day MA of 6.60, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 53.84 is Neutral, neither overbought nor oversold. The STOCH value of 62.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALT.

Altimmune Risk Analysis

Altimmune disclosed 64 risk factors in its most recent earnings report. Altimmune reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Altimmune Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$490.83M12.2420.50%2333.50%
52
Neutral
$5.04B3.15-44.58%2.85%16.08%-0.27%
ALALT
52
Neutral
$462.31M-57.28%-95.12%21.09%
IVIVA
50
Neutral
$488.85M344.74%-47.32%-26.67%
45
Neutral
$324.69M-49.97%-14.16%25.80%
43
Neutral
$345.84M-48.45%7.15%
33
Underperform
$401.49M-71.44%19.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALT
Altimmune
5.58
-2.43
-30.34%
AUTL
Autolus Therapeutics
1.29
-3.10
-70.62%
STOK
Stoke Therapeutics
9.76
-4.14
-29.78%
ORIC
Oric Pharmaceuticals
4.73
-4.43
-48.36%
IVA
Inventiva
3.11
-0.68
-17.94%
SANA
Sana Biotechnology
1.74
-6.99
-80.07%

Altimmune Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: -7.15%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call highlighted the anticipation for the IMPACT Phase 2b NASH trial results and financial strategies to support development. The expansion into AUD and ALD also shows growth potential. However, net losses and R&D expenses remain concerns.
Q1-2025 Updates
Positive Updates
Upcoming Readout of IMPACT Phase 2b NASH Trial
The trial aims to show statistical significance on NASH endpoints at 24 weeks, a first among incretins, and combines these effects with clinically meaningful weight loss.
Credit Facility with Hercules Capital
Altimmune entered a credit facility for up to $100 million, providing financial flexibility to support the development of pemvidutide.
Successful Enrollment in IMPACT Phase 2b Trial
The trial enrolled 212 participants, exceeding the original target and increasing study power.
Potential Expansion into AUD and ALD
Plans for Phase 2 trials in Alcohol Use Disorder and Alcohol Liver Disease, areas with significant unmet medical needs, were unveiled, potentially expanding pemvidutide's application.
Strong Financial Position
Altimmune ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, an increase from $132 million at year-end 2024.
Negative Updates
Net Loss in Q1 2025
The company reported a net loss of $19.6 million or $0.26 per share, compared to a net loss of $24.4 million or $0.34 per share in the first quarter of 2024.
R&D Expenses
R&D expenses were $15.8 million for Q1 2025, a decrease from $21.5 million in the same period of 2024, primarily due to upfront CRO costs for the IMPACT trial.
Company Guidance
During Altimmune's first quarter 2025 financial results conference call, the company provided optimistic guidance on several fronts. The firm anticipates announcing the results of its IMPACT Phase 2b NASH trial this quarter, with expectations of achieving statistical significance at 24 weeks for both NASH endpoints and clinically meaningful weight loss. The company also revealed a new $100 million credit facility with Hercules Capital, bolstering their financial position to support ongoing and future trials. Altimmune is planning Phase 2 trials for alcohol use disorder (AUD) and alcohol liver disease (ALD) within the second and third quarters of 2025, respectively. The company's cash balance increased to $150 million, supported by a $35 million raise from an ATM facility in the first quarter. Further, they reported a net loss of $19.6 million for the quarter, an improvement from the previous year's $24.4 million. Altimmune's leadership emphasized the potential of their lead candidate, pemvidutide, to be a transformative treatment across multiple fibrotic liver diseases, highlighting the drug's unique profile combining liver fat reduction and weight loss.

Altimmune Corporate Events

Private Placements and FinancingFinancial Disclosures
Altimmune Secures $100 Million Credit Facility
Positive
May 13, 2025

On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Spark’s Take on ALT Stock

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

Altimmune’s strong balance sheet and promising clinical pipeline are positive, but challenges remain with profitability and cash flow. Technical indicators are neutral, while the earnings call provides some optimism for future growth.

To see Spark’s full report on ALT stock, click here.

Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Altimmune Reports 2024 Financial Results and R&D Progress
Positive
Feb 27, 2025

Altimmune announced its financial results for the fourth quarter and full year of 2024, highlighting significant progress in the development of pemvidutide. The company completed enrollment for the Phase 2b IMPACT trial in MASH and expects to report top-line data in Q2 2025. Additionally, Altimmune received FDA clearance for investigational new drug applications in two more indications, with Phase 2 trials slated for mid-2025. The company also strengthened its board with two new pharmaceutical industry veterans and plans to host a virtual R&D Day on March 13, 2025, to discuss further developments.

Executive/Board ChangesBusiness Operations and Strategy
Altimmune Expands Board Amid Late-Stage Drug Development
Positive
Feb 25, 2025

On February 24, 2025, Altimmune, Inc. expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, both seasoned executives in the biopharmaceutical industry. This strategic move comes as the company progresses into late-stage clinical development of pemvidutide, a promising treatment for liver and metabolic diseases. Lawver and Durso bring extensive experience in commercialization and corporate strategy, which is expected to bolster Altimmune’s efforts in transitioning to a pre-commercial-stage organization and advancing its strategic vision.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.